Biomarkers of Endometrial Receptivity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

476 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers in Endometriosis

NCT04591548

Endometriosis

COMPLETED

Transcriptomic Evaluation of Endometrial Receptivity

NCT04141085

Infertility, Female

COMPLETED

Development of a Microbiome Non-invasive Diagnosis Tool

NCT03330444

Infertility of Uterine Origin

COMPLETED

Predicting Endometrial Receptivity for Optimal Reproductive Management

NCT04107129

Infertility, Female Endometriosis

COMPLETED

New Strategies to Evaluate the Reproductive Tract Microbiome

NCT06920797

Fertility Infertility Reproductive Health +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Successful implantation depends on synchronization between a normal functional embryo at the blastocyst developmental stage and a receptive endometrium. The endometrium is receptive to blastocysts during a spatially and temporally restricted time window called the "window of implantation". Failure of the endometrium to attain receptivity is one cause of infertility, and this is not currently assessed during infertility workup due to a lack of reliable markers for receptivity. Better tests are required to assist the clinician with the decision when to defer a transfer and to freeze all embryos. Proteomics, or the analysis of the proteins in any sample, provides physiologically relevant information, since there are many regulatory steps between the transcriptome and functional proteins. Uterine fluid is a protein-rich histotroph that contains, among other components, secretions from the endometrial glands and cleavage products of both the secreted proteins and the glycocalyx. The aim of this study is to assess the highly sensitive mass spectrometer analysis of the proteins from cervical mucus for the detection of defects in endometrial receptivity and search for new endometrial receptivity biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IVF Infertility Treatment Fertility Disorders Embryo Transfer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A: Patients undergo cycle with the transfer of fresh embryos

In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)/embryo transfer (ET) cycle with the transfer of fresh embryos.

Group Type EXPERIMENTAL

Cervical mucus will be collected from patients undergoing IVF

Intervention Type DIAGNOSTIC_TEST

Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.

B: Patients undergo cycle with the transfer of frozen embryos

In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.

Group Type EXPERIMENTAL

Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos

Intervention Type DIAGNOSTIC_TEST

Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cervical mucus will be collected from patients undergoing IVF

Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.

Intervention Type DIAGNOSTIC_TEST

Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos

Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* female aged less than 37 years (maximally 36y + 364d)
* no smoker
* normal menstrual cycles lasting between 25 to 35 days
* had been infertile for less than five years
* normal responder
* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF/ intracytoplasmic sperm injection (ICSI) embryo transfer cycles and/or frozen-thawed embryo transfer cycles
* sperm obtained through ejaculation
* spermiogram more than 5 million sperm/mL
* BMI 19-29 kg/m2
* follicle stimulating hormone (FSH) \< 10 IU/L on the third day
* basal antral follicle count of 5-15
* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol
* informed consent

* female aged less than 37 years (maximally 36y + 364d)
* no smoker
* normal menstrual cycles lasting between 25 to 35 days
* had been infertile for less than five years
* normal responder at stimulation
* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF/ intracytoplasmic sperm injection (ICSI) embryo transfer cycles and/or frozen-thawed embryo transfer cycles
* sperm obtained through ejaculation
* spermiogram more than 5 million sperm/mL
* BMI 19-29 kg/m2
* FSH \< 10 IU/L on the third day
* undergoing the same routine estrogen/progesterone substituted cycle
* informed consent

Exclusion Criteria

* genetic disease
* metabolic and/or endocrine disorders
* polycystic ovary syndrome (defined by the Rotterdam criteria)
* women with prior diagnosis of endometriosis or adenomyosis
* previous gynecological/pelvic surgery except for salpingectomy
* repeated spontaneous abortions (two or more)
* previously less than 5 oocytes and/or serum anti-Mullerian hormone value \< 1.0 mIU/ml or more than 20 oocytes, milli-International unit (mIU)
* previous ovarian hyperstimulation syndrome (OHSS)
* presence of any structural abnormality of the reproductive system
* donor oocyte cycles
* severe male factor infertility \< 5 million sperm/mL
* low response to stimulation
* endometrium \< 8 mm at the day of human chorionic gonadotropin (hCG) or ET
* number of retrieved oocytes 5 - 20
* low fertilization capacity (rate of fertilization \< 20% and late ICSI following IVF fertilization failure)
* OHSS
* IVF cycle cancelled before ET
* other than easy one high-quality blastocyst transfer (at least grade 3BB)

* genetic disease
* metabolic and/or endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders
* polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia
* women with prior diagnosis of endometriosis or adenomyosis
* previous gynecological/pelvic surgery except for salpingectomy
* repeated spontaneous abortions (two or more)
* previously less than 5 oocytes and/or serum anti-Mullerian hormone value \< 0.5 mIU/ml in the stimulated cycle
* previous OHSS
* presence of any structural abnormality of the reproductive system
* severe male factor infertility \< 5 million sperm/mL in the stimulated cycle
* number of retrieved oocytes 5 - 20 in the stimulated cycle
* low fertilization capacity (rate of fertilization \< 20% and late ICSI following IVF fertilization failure)
* endometrium less than 8 mm at the day of thawing and transfer indication
* thawed blastocyst cycle cancelled before ET
* other than easy one best quality frozen/thawed blastocyst transfer (at least grade 3BB)

Maximum Eligible Age

36 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No